BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18466425)

  • 1. Current status and impact of CMV prevention following pediatric organ transplantation.
    Allen UD
    Pediatr Transplant; 2008 Jun; 12(4):389-92. PubMed ID: 18466425
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
    Mwintshi K; Brennan DC
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cytomegalovirus following solid organ transplantation: a literature review.
    Kowalsky S; Arnon R; Posada R
    Pediatr Transplant; 2013 Sep; 17(6):499-509. PubMed ID: 23890075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: are we winning the battle only to lose the war?
    Singh N
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):643-6. PubMed ID: 12373496
    [No Abstract]   [Full Text] [Related]  

  • 5. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
    Yu MA; Park JM
    Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
    Meylan PR; Pascual M
    Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
    [No Abstract]   [Full Text] [Related]  

  • 7. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.
    Small LN; Lau J; Snydman DR
    Clin Infect Dis; 2006 Oct; 43(7):869-80. PubMed ID: 16941368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
    Freeman RB
    Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection in organ transplant recipients.
    Hibberd PL; Snydman DR
    Infect Dis Clin North Am; 1995 Dec; 9(4):863-77. PubMed ID: 8747770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation.
    Wagner JA; Ross H; Hunt S; Gamberg P; Valantine H; Merigan TC; Stinson EB
    Transplantation; 1995 Dec; 60(12):1473-7. PubMed ID: 8545877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation.
    Andrews PA; Emery VC; Newstead C
    Transplantation; 2011 Dec; 92(11):1181-7. PubMed ID: 22002346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.
    Reischig T
    Expert Rev Anti Infect Ther; 2012 Jan; 10(1):51-61. PubMed ID: 22149614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
    Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
    Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
    Boivin G; Goyette N; Gilbert C; Humar A; Covington E
    Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term care after hematopoietic-cell transplantation in adults.
    Boeckh M; Nichols WG; Marr KA
    N Engl J Med; 2002 Nov; 347(20):1625-6; author reply 1625-6. PubMed ID: 12432056
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients: is emergence of resistance imminent?
    Singh N; Yu VL
    Dig Dis Sci; 1998 Jun; 43(6):1190-2. PubMed ID: 9635606
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytomegalovirus in transplantation - challenging the status quo.
    Fishman JA; Emery V; Freeman R; Pascual M; Rostaing L; Schlitt HJ; Sgarabotto D; Torre-Cisneros J; Uknis ME
    Clin Transplant; 2007; 21(2):149-58. PubMed ID: 17425738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Organ transplantation infection and its prevention and treatment].
    Wang E; Liu Y
    Zhonghua Nei Ke Za Zhi; 1996 May; 35(5):350-2. PubMed ID: 9387619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.